Eric Kelsic, PhD is CEO and Cofounder of Dyno Therapeutics. Prior to founding Dyno in 2018, Eric led a team to develop the technology underlying Dyno’s artificial intelligence powered capsid engineering platform in George Church’s lab at the Wyss Institute of Harvard Medical School. There he measured the first comprehensive fitness landscape of the adeno-associated virus (AAV) capsid protein and co-discovered the AAV MAAP gene. He earned a PhD in Systems Biology from Harvard University and a BS in Physics from Caltech. Under Eric’s leadership Dyno has raised over $100M in VC financing, including a 2021 Series A led by a16z and signed partnership with leading gene therapy companies (including Novartis, Sarepta, Roche and Astellas). Dyno was named Xconomy’s 2020 Startup of the Year and Eric was recognized as one of Endpoint’s 20 under 40 next-gen biotech leaders in 2021.